BR112014010009A2 - "anticorpo que se liga a cd44, seus métodos de produção e usos no tratamento ou prevenção de malignidade hematológica ou leucemia linfocítica crônica, método de alvejar anticorpo, kit de detecção, bem como composição farmacêutica, molécula de ácido nucleico e vetor de expressão" - Google Patents
"anticorpo que se liga a cd44, seus métodos de produção e usos no tratamento ou prevenção de malignidade hematológica ou leucemia linfocítica crônica, método de alvejar anticorpo, kit de detecção, bem como composição farmacêutica, molécula de ácido nucleico e vetor de expressão"Info
- Publication number
- BR112014010009A2 BR112014010009A2 BR112014010009A BR112014010009A BR112014010009A2 BR 112014010009 A2 BR112014010009 A2 BR 112014010009A2 BR 112014010009 A BR112014010009 A BR 112014010009A BR 112014010009 A BR112014010009 A BR 112014010009A BR 112014010009 A2 BR112014010009 A2 BR 112014010009A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- lymphocytic leukemia
- antibody
- prevention
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
resumo patente de invenção: "cd44 anticorpo monoclonal para tratamento de leucemia linfocítica crônica de célula-b e de outras malignidades hematológicas". composições, incluindo um anticorpo específico para cd44 são providas. estes anticorpos ligam-se especificamente a células malignas hematológicas. métodos para usar os anticorpos cd44 a células-alvo expressando cd44 para fins terapêuticos e de diagnósticos também são providos. 21118337v1 1/1 21118337v1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161551852P | 2011-10-26 | 2011-10-26 | |
PCT/US2012/062266 WO2013063498A1 (en) | 2011-10-26 | 2012-10-26 | Cd44 monoclonal antibody for the treatment of b-cell chronic lymphocytic leukemia and other hematological malignancies |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014010009A2 true BR112014010009A2 (pt) | 2017-04-25 |
Family
ID=47143316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014010009A BR112014010009A2 (pt) | 2011-10-26 | 2012-10-26 | "anticorpo que se liga a cd44, seus métodos de produção e usos no tratamento ou prevenção de malignidade hematológica ou leucemia linfocítica crônica, método de alvejar anticorpo, kit de detecção, bem como composição farmacêutica, molécula de ácido nucleico e vetor de expressão" |
Country Status (13)
Country | Link |
---|---|
US (1) | US20140308301A1 (pt) |
EP (1) | EP2771363A1 (pt) |
JP (1) | JP2014534221A (pt) |
KR (1) | KR20140090997A (pt) |
CN (1) | CN103946239A (pt) |
AU (1) | AU2012328512A1 (pt) |
BR (1) | BR112014010009A2 (pt) |
CA (1) | CA2851545A1 (pt) |
IL (1) | IL231902A0 (pt) |
MX (1) | MX2014004969A (pt) |
RU (1) | RU2014120577A (pt) |
SG (1) | SG11201401405PA (pt) |
WO (1) | WO2013063498A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI535452B (zh) | 2015-01-23 | 2016-06-01 | 長庚醫療財團法人 | 使用抗-cd44中和抗體來治療和/或預防心房顫動 |
EP4335918A3 (en) * | 2015-04-03 | 2024-04-17 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
EP4153192A1 (en) | 2020-05-19 | 2023-03-29 | Institut Curie | Methods for the diagnosis and treatment of cytokine release syndrome |
WO2022243838A1 (en) | 2021-05-18 | 2022-11-24 | Janssen Biotech, Inc. | Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4631190A (en) | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US6287569B1 (en) | 1997-04-10 | 2001-09-11 | The Regents Of The University Of California | Vaccines with enhanced intracellular processing |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
US20050100542A1 (en) * | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US8071072B2 (en) * | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US8048416B2 (en) * | 1999-10-08 | 2011-11-01 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US20050031610A1 (en) * | 2002-07-19 | 2005-02-10 | Tae-Wan Kim | CD44-related fragments, compositions and methods |
WO2005046597A2 (en) * | 2003-11-07 | 2005-05-26 | Brigham And Womens's Hospital, Inc. | Antibodies to cd44 glycoforms and uses thereof |
EP1532984A1 (en) * | 2003-11-19 | 2005-05-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia |
WO2010058396A1 (en) * | 2008-11-19 | 2010-05-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | A cd44vra antibody and diagnostic and therapeutic methods using same |
BR112012019475A8 (pt) * | 2010-02-04 | 2017-12-26 | Hoffmann La Roche | uso de um anticorpo monoclonal anti-cd44, anticorpo monoclonal anti-cd44, anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra |
-
2012
- 2012-10-26 BR BR112014010009A patent/BR112014010009A2/pt not_active Application Discontinuation
- 2012-10-26 EP EP12781555.3A patent/EP2771363A1/en not_active Withdrawn
- 2012-10-26 JP JP2014539084A patent/JP2014534221A/ja not_active Ceased
- 2012-10-26 MX MX2014004969A patent/MX2014004969A/es unknown
- 2012-10-26 CA CA2851545A patent/CA2851545A1/en not_active Abandoned
- 2012-10-26 WO PCT/US2012/062266 patent/WO2013063498A1/en active Application Filing
- 2012-10-26 KR KR1020147012535A patent/KR20140090997A/ko not_active Application Discontinuation
- 2012-10-26 SG SG11201401405PA patent/SG11201401405PA/en unknown
- 2012-10-26 RU RU2014120577/10A patent/RU2014120577A/ru not_active Application Discontinuation
- 2012-10-26 US US14/354,472 patent/US20140308301A1/en not_active Abandoned
- 2012-10-26 CN CN201280052997.4A patent/CN103946239A/zh active Pending
- 2012-10-26 AU AU2012328512A patent/AU2012328512A1/en not_active Abandoned
-
2014
- 2014-04-03 IL IL231902A patent/IL231902A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20140090997A (ko) | 2014-07-18 |
US20140308301A1 (en) | 2014-10-16 |
WO2013063498A1 (en) | 2013-05-02 |
EP2771363A1 (en) | 2014-09-03 |
CA2851545A1 (en) | 2013-05-02 |
SG11201401405PA (en) | 2014-05-29 |
MX2014004969A (es) | 2014-05-30 |
RU2014120577A (ru) | 2015-12-10 |
JP2014534221A (ja) | 2014-12-18 |
IL231902A0 (en) | 2014-05-28 |
CN103946239A (zh) | 2014-07-23 |
AU2012328512A1 (en) | 2014-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018077362A2 (pt) | conjugados para edição de superfície de célula-alvo | |
BR112014010009A2 (pt) | "anticorpo que se liga a cd44, seus métodos de produção e usos no tratamento ou prevenção de malignidade hematológica ou leucemia linfocítica crônica, método de alvejar anticorpo, kit de detecção, bem como composição farmacêutica, molécula de ácido nucleico e vetor de expressão" | |
BR112012024710A8 (pt) | moléculas que se ligam ao antígeno, seus processos de produção, bem como composição farmacêutica que as compreendem | |
CY1117236T1 (el) | Μονοκλωνικα αντισωματα εναντι γλυπικανης-3 | |
CY1119539T1 (el) | Πληρως ανθρωπινα αντισωματα ειδικα για to cadμ1 | |
BR112013008480A2 (pt) | anticorpos contra tumor e usos específicos dos mesmos | |
BR112012009854B8 (pt) | proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, método de confecção da referida proteína de ligação e uso da mesma | |
BR112012004823A8 (pt) | Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica | |
BR112012018413A2 (pt) | 1h-pirazol[3,4-b]piridinas e usos terapêuticos dos mesmos. | |
BR112017010110A2 (pt) | anticorpos contra cd73 e usos do mesmo | |
BRPI0606547A2 (pt) | anticorpo 2h7 humanizado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para a produção do anticorpo, composição, artigo manufaturado, metódos de tratamento, formulações lìquidas e usos do anticorpo 2h7 humanizado | |
MX2009003306A (es) | Anticuerpos humanos que se unen a cxcr4 y sus usos. | |
AR088514A1 (es) | Inmunoligantes biespecificos dirigidos contra tnf | |
EA201590207A1 (ru) | Композиции и способы регуляции car-т-клеток | |
CL2009000379A1 (es) | Anticuerpo monoclonal aislado especifico contra los ligandos angiopoyetina 1 y 2 del receptor tie 2; fragmento del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para inhibir la angiogenesis no deseada tal como cancer. | |
BR112012018132A2 (pt) | "marcadores de células - tronco tumorais e uso dos mesmos". | |
BR112014007382A2 (pt) | anticorpos anti-erbb3 e seus usos | |
WO2007067992A3 (en) | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 | |
UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
MX2009005189A (es) | Anticuerpos humanos monoclonales para btla y metodos de uso. | |
BR112015012987A2 (pt) | composições compreendendo anticorpos anti-cd38 e lenalidomida | |
BR112012023660A2 (pt) | novos métodos para direcionar células-tronco cancerosas | |
BR112012007322A2 (pt) | composto de 2-piridona usados como inibidores de neutrófilo elastase | |
BR112015022529A2 (pt) | meios de cultura de células e processos de produção de anticorpo | |
BR112012022258A2 (pt) | anticorpos monoclonais otimizados contra inibidor de trajetória de fator de tecido ( tfpi) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |